Literature DB >> 12127957

Second malignancies after allogeneic hematopoietic stem cell transplantation: new insight and current problems.

L Adès1, P Guardiola, G Sociè.   

Abstract

With increased number of patients surviving on the long term, late effect after allogeneic hematopoietic stem cell transplantation have become of major clinical importance. Among these late effect, second malignancies have increasingly been recognized in the recent years. It has been usual to divide the problem of secondary malignancies following hematopoietic stem cell transplantation into three groups, i.e. leukemia, lymphoma and solid tumors. Recent clinical and biological data on these three types of malignancies, occurring after allogeneic stem cell transplantation, are summarized in this review. We will focus here only on second malignancies after allogeneic stem cell transplantation with particular emphasis on recent development on the pathogenesis, and early diagnosis, and treatment of these transplant-related complications.

Entities:  

Mesh:

Year:  2002        PMID: 12127957     DOI: 10.1054/blre.2002.0010

Source DB:  PubMed          Journal:  Blood Rev        ISSN: 0268-960X            Impact factor:   8.250


  12 in total

1.  Increased risk of breast cancer among survivors of allogeneic hematopoietic cell transplantation: a report from the FHCRC and the EBMT-Late Effect Working Party.

Authors:  Debra L Friedman; Alicia Rovo; Wendy Leisenring; Anna Locasciulli; Mary E D Flowers; Andre Tichelli; Jean E Sanders; H Joachim Deeg; Gerard Socie
Journal:  Blood       Date:  2007-10-02       Impact factor: 22.113

2.  Late effects of myeloablative bone marrow transplantation (BMT) in sickle cell disease (SCD).

Authors:  Courtney D Fitzhugh; Shira Perl; Matthew M Hsieh
Journal:  Blood       Date:  2008-02-01       Impact factor: 22.113

Review 3.  On the origin of cancer metastasis.

Authors:  Thomas N Seyfried; Leanne C Huysentruyt
Journal:  Crit Rev Oncog       Date:  2013

4.  Impact of chronic GVHD therapy on the development of squamous-cell cancers after hematopoietic stem-cell transplantation: an international case-control study.

Authors:  Rochelle E Curtis; Catherine Metayer; J Douglas Rizzo; Gérard Socié; Kathleen A Sobocinski; Mary E D Flowers; William D Travis; Lois B Travis; Mary M Horowitz; H Joachim Deeg
Journal:  Blood       Date:  2005-02-01       Impact factor: 22.113

5.  5-Azacytidine depletes HSCs and synergizes with an anti-CD117 antibody to augment donor engraftment in immunocompetent mice.

Authors:  Andriyana K Bankova; Wendy W Pang; Brenda J Velasco; Janel R Long-Boyle; Judith A Shizuru
Journal:  Blood Adv       Date:  2021-10-12

Review 6.  Perspectives on the mesenchymal origin of metastatic cancer.

Authors:  Leanne C Huysentruyt; Thomas N Seyfried
Journal:  Cancer Metastasis Rev       Date:  2010-12       Impact factor: 9.264

Review 7.  Stem cells and cancer: evidence for bone marrow stem cells in epithelial cancers.

Authors:  Han-Chen Li; Calin Stoicov; Arlin B Rogers; JeanMarie Houghton
Journal:  World J Gastroenterol       Date:  2006-01-21       Impact factor: 5.742

8.  [Late effects after chemotherapy].

Authors:  W Pönisch; D Niederwieser
Journal:  Internist (Berl)       Date:  2006-03       Impact factor: 0.743

9.  Risk factors in the development of stem cell therapy.

Authors:  Carla A Herberts; Marcel S G Kwa; Harm P H Hermsen
Journal:  J Transl Med       Date:  2011-03-22       Impact factor: 5.531

10.  Establishment of animal model for the analysis of cancer cell metastasis during radiotherapy.

Authors:  Jong Kuk Park; Su Jin Jang; Sung Wook Kang; Sunhoo Park; Sang-Gu Hwang; Wun-Jae Kim; Joo Hyun Kang; Hong-Duck Um
Journal:  Radiat Oncol       Date:  2012-09-11       Impact factor: 3.481

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.